Replimune Group Inc (REPL)
NASDAQ:REPL

Replimune Group (REPL) AI Stock Analysis

Compare
262 Followers

Top Page

RE

Replimune Group

(NASDAQ:REPL)

40Neutral
Replimune Group's overall score reflects its early-stage development status within the biotechnology sector. The company shows strong equity positioning but faces significant operational losses typical for firms investing heavily in R&D. Technical indicators suggest bearish momentum, emphasizing current market caution. Valuation metrics are impacted by negative earnings, aligning with its developmental phase. Successful product commercialization will be critical for future performance improvement.
Positive Factors
Clinical Trials
RP1 + Opdivo achieved an objective response rate (ORR) of 33.6%, which is significantly higher than what would be expected with an anti-PD1 agent alone in an anti-PD1-refractory melanoma population.
Financial Stability
Replimune's improved cash balance further solidifies the company's position heading into the potential launch of RP1.
Regulatory Approval
The FDA granted breakthrough therapy designation for RP1 + nivolumab in anti-PD-1-failed melanoma.
Negative Factors
Development Costs
Replimune guides to sufficient cash runway to fund operations into 4Q26, accounting for the costs associated with scaling up for the potential commercialization of RP1 in skin cancers.
Market Competition
Replimune's RP1 + Opdivo combination therapy shows potential differentiation against other treatments like Amtagvi™ due to its efficacy and safety profile.
Regulatory Process
The FDA has accepted REPL's BLA for RP1 and granted priority review, with a PDUFA date set for July 22, 2025.

Replimune Group (REPL) vs. S&P 500 (SPY)

Replimune Group Business Overview & Revenue Model

Company DescriptionReplimune Group, Inc. (REPL) is a biotechnology company focused on developing oncolytic immunotherapies for the treatment of cancer. The company operates in the healthcare sector, specifically within the biopharmaceutical industry. Replimune's core products are based on its proprietary Immulytic platform, which is designed to enhance the systemic anti-tumor immune response by using genetically engineered viruses to selectively infect and kill cancer cells while sparing normal tissue.
How the Company Makes MoneyReplimune Group generates revenue primarily through partnerships, collaborations, and licensing agreements with other pharmaceutical and biotechnology companies. These partnerships often involve upfront payments, milestone payments, and potential royalties based on the successful development and commercialization of their oncolytic immunotherapies. While Replimune is still in the clinical trial phase for many of its product candidates, such collaborations are crucial for funding ongoing research and development activities. Additionally, the company may also receive government grants or funding from cancer research organizations to support its innovative work in oncolytic virotherapy.

Replimune Group Financial Statement Overview

Summary
Replimune Group is in an early growth stage, heavily investing in R&D, which impacts profitability and cash flow. While the company maintains a strong equity position, it experiences significant operational losses typical for its industry phase. Future financial performance will depend on successful product development and commercialization.
Income Statement
30
Negative
Replimune Group has shown minimal revenue with a TTM revenue of $4.04 million, indicating an initial phase of commercial operations. The company is experiencing significant negative EBIT and EBITDA margins due to high operating expenses, typical for biotechnology firms in research phases. Net profit margins are also deeply negative, reflecting ongoing losses as the company invests heavily in R&D.
Balance Sheet
45
Neutral
The balance sheet shows a strong equity position relative to liabilities, with a debt-to-equity ratio of 0.06 in TTM. The equity ratio stands at 79.9%, indicating a low leverage. However, substantial net losses contribute to a low return on equity, typical for companies heavily investing in development before achieving commercial success.
Cash Flow
35
Negative
Operating cash flow remains negative, reflecting cash outflows associated with R&D activities. Despite this, the company has managed robust financing activities, maintaining liquidity with significant cash reserves. Free cash flow has shown a marginal decline, emphasizing the need for efficient cash management to support ongoing operations.
Breakdown
TTMMar 2024Mar 2023Mar 2022Mar 2021Mar 2020
Income StatementTotal Revenue
4.04M0.000.000.000.000.00
Gross Profit
2.65M-2.65M-2.45M-4.58M-4.14M-1.81M
EBIT
-241.06M-234.77M-177.08M-118.31M-79.95M-56.20M
EBITDA
-217.67M-230.20M-170.30M-114.41M-76.48M-52.60M
Net Income Common Stockholders
-228.24M-215.79M-174.28M-118.04M-80.87M-52.63M
Balance SheetCash, Cash Equivalents and Short-Term Investments
20.59M420.67M583.39M395.65M476.30M168.56M
Total Assets
22.82M487.72M646.59M461.19M543.10M234.10M
Total Debt
0.0075.87M60.76M32.84M33.28M41.79M
Net Debt
-20.59M1.41M-85.83M-73.11M-149.24M-17.71M
Total Liabilities
1.99M113.21M91.30M49.96M44.37M50.38M
Stockholders Equity
20.76M374.51M555.29M411.23M498.73M183.72M
Cash FlowFree Cash Flow
-191.98M-191.13M-130.32M-84.52M-63.78M-67.09M
Operating Cash Flow
-184.69M-185.47M-128.05M-82.18M-61.39M-60.55M
Investing Cash Flow
7.11M97.20M-142.50M-1.81M-188.78M-5.23M
Financing Cash Flow
252.40M16.28M311.30M6.60M372.46M100.17M

Replimune Group Technical Analysis

Technical Analysis Sentiment
Negative
Last Price7.46
Price Trends
50DMA
12.26
Negative
100DMA
12.24
Negative
200DMA
11.35
Negative
Market Momentum
MACD
-0.81
Positive
RSI
21.05
Positive
STOCH
7.02
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For REPL, the sentiment is Negative. The current price of 7.46 is below the 20-day moving average (MA) of 10.52, below the 50-day MA of 12.26, and below the 200-day MA of 11.35, indicating a bearish trend. The MACD of -0.81 indicates Positive momentum. The RSI at 21.05 is Positive, neither overbought nor oversold. The STOCH value of 7.02 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for REPL.

Replimune Group Risk Analysis

Replimune Group disclosed 57 risk factors in its most recent earnings report. Replimune Group reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Replimune Group Peers Comparison

Overall Rating
UnderperformOutperform
Sector (48)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
62
Neutral
$800.15M-56.17%-34.57%-6.31%
48
Neutral
$6.36B1.09-49.92%2.63%17.17%0.95%
42
Neutral
$671.44M-70.98%249.53%56.59%
41
Neutral
$686.32M-54.00%59.55%3.09%
40
Neutral
$574.53M-50.50%4.28%
40
Underperform
$612.31M-34.74%-36.72%-64.37%
29
Underperform
$545.94M-54.14%6.99%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
REPL
Replimune Group
7.46
0.34
4.78%
CMRX
Chimerix
8.53
7.53
753.00%
XNCR
Xencor
8.69
-12.81
-59.58%
RCKT
Rocket Pharmaceuticals
5.12
-19.27
-79.01%
NTLA
Intellia Therapeutics
6.63
-18.67
-73.79%
PRAX
Praxis Precision Medicines
32.65
-21.04
-39.19%

Replimune Group Corporate Events

Product-Related AnnouncementsRegulatory Filings and Compliance
Replimune Group Advances Cancer Treatment with FDA Submission
Positive
Nov 21, 2024

Replimune Group, Inc. has made significant strides in cancer treatment with its submission of a biologics license application to the FDA for its lead product, RP1, in combination with nivolumab, targeting advanced melanoma. The FDA has granted Breakthrough Therapy designation to this innovative therapy, which could expedite its availability for patients with limited options. This development marks a promising advancement for Replimune, as their novel oncolytic immunotherapy shows potential for substantial improvement over existing treatments.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.